2021
Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy
Wells CR, Cao Y, Durham DP, Byrareddy SN, Ansari AA, Ruddle NH, Townsend JP, Galvani AP, Perelson AS. Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy. PLOS Computational Biology 2021, 17: e1009031. PMID: 34106916, PMCID: PMC8189501, DOI: 10.1371/journal.pcbi.1009031.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyViral loadPost-treatment controlAnti-α4β7 antibodyViral remissionAntibody treatmentViral controlCombinations of cARTImmune effector cell responsesPost-treatment viral controlSIV RNA copies/Depletion of CD8Ongoing immune responseEarly SIV infectionRNA copies/Stable viral loadEffector cell responsesViral load dataDifferent viral loadsAbsence of treatmentSubset of animalsNonhuman primate experimentsDifferent primary mechanismsLongitudinal viral load dataCART cessation
2015
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases 2015, 62: 298-304. PMID: 26628566, PMCID: PMC4706637, DOI: 10.1093/cid/civ894.Peer-Reviewed Original ResearchConceptsHepatitis C virusInterferon-free DAAsHCV incidenceTreatment ratesChronic hepatitis C virusCases of cirrhosisInjection drug useImpact of administrationAnnual treatment ratesEnhanced screeningHCV prevalenceHCV screeningDecompensated cirrhosisHCV infectionHCV transmissionHepatitis CLiver transplantActing antiviralsLevels of screeningPatients 4C virusHepatocellular carcinomaEpidemiological dataUniversal screeningDrug use